# Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

> **NCT02501551** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 36 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** regorafenib

## Key facts

- **NCT ID:** NCT02501551
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2022-05
- **Final completion:** 2022-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02501551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02501551, "Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02501551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*